CAMBRIDGE: Obsidian Therapeutics, Inc., a trailblazer in engineered cell and gene therapies, has successfully completed a $160.5 million Series C financing round. This round was notably oversubscribed and led by Wellington Management, a new investor in the company. The funding round saw participation from a host of new investors, including Foresite Capital, Janus Henderson Investors,…